YES1
ENSG00000176105
Target class
Kinase
Chromosome
18
Approved drugs
1
Clinical candidates (approved and in development)
6
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- Yes
- Target name
- YES1
- Gene name
- YES proto-oncogene 1, Src family tyrosine kinase
- Gene symbol
- YES1
- Protein name
- Tyrosine-protein kinase Yes (EC 2.7.10.2) (Proto-oncogene c-Yes) (p61-Yes)
- Yes
- c-yes
- HsT441
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing|Src family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 38.39
- Tissue specificity (Gini)
- 0.264
- Tissue specificity (tau)
- 0.582
- KEGG gene identifiers
- hsa:7525
- Protein interaction confidence
- 0.818533
- Protein interaction partners
- 30
- R-HSA-1227986
- R-HSA-1433557
- R-HSA-1433559
- R-HSA-2029481
- R-HSA-210990
- R-HSA-2682334
- R-HSA-389356
- R-HSA-389513
- R-HSA-3928662
- R-HSA-3928663
- R-HSA-3928665
- R-HSA-8940973
- R-HSA-912631
- R-HSA-9664323
- R-HSA-9664422
- R-HSA-9670439
- R-HSA-9680350
- End position
- 813276
- Start position
- 721588
- Chromosome
- 18
- Strand
- Reverse
- Cell membrane. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytosol. Cell junction . Note=Newly synthesized protein initially accumulates in the Golgi region and traffics to the plasma membrane through the exocytic pathway. Localized to small puncta throughout the cytoplasm and cell membrane when in the presence of SNAIL1 (By similarity). .
- Cytosol
- Plasma membrane
- Tissue specificity (tau)
- 0.582134
- Expression inequality (Gini)
- 0.263531
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 38.39
- Adipose - Subcutaneous
- 31.51
- Lung
- 31.14
- Adipose - Visceral (Omentum)
- 30.87
- Breast - Mammary Tissue
- 29.52
Expression in transcripts per million
- Cells - Cultured fibroblasts38.39
- Adipose - Subcutaneous31.51
- Lung31.14
- Adipose - Visceral (Omentum)30.87
- Breast - Mammary Tissue29.52
- Thyroid24.95
- Testis24.89
- Cervix - Ectocervix24.42
- Esophagus - Mucosa24.23
- Cervix - Endocervix23.58
- Uterus23.36
- Vagina23.11
- Spleen22.57
- Minor Salivary Gland21.75
- Colon - Sigmoid19.8
- Bladder19.6
- Skin - Sun Exposed (Lower leg)18.67
- Fallopian Tube18.55
- Nerve - Tibial18.31
- Esophagus - Muscularis18.26
- Kidney - Medulla18.05
- Brain - Spinal cord (cervical c-1)18.01
- Ovary17.99
- Colon - Transverse17.72
- Skin - Not Sun Exposed (Suprapubic)17.63
And 29 more, listed on the interactive page.
- GO:0002862
- GO:0031295
- GO:0036211
- GO:0038096
- GO:0043114
- GO:0048013
- GO:0050900
- GO:0005794
- GO:0005829
- GO:0005886
- GO:0005925
- GO:0070062
- GO:0001784
- GO:0004713
- GO:0004715
- GO:0005515
- GO:0019899
- GO:0044325
Related records
Trials (770)
- A Bioequivalence Study of Dasatinib Tablet
- A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
- A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)
- A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
- A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
- A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
- A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
- A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Drugs (14)
- Dasatinib
- Dasatinib anhydrous SRC inhibitor
- Dasatinib laurylsulfate SRC inhibitor
- ENMD-981693 SRC inhibitor
- Ibrutinib
- Ilorasertib SRC inhibitor
- JNJ-26483327 Tyrosine-protein kinase YES inhibitor
- Nefextinib
- Nemtabrutinib
- Rebastinib
- Saracatinib
- Spebrutinib
- TG100-801 SRC inhibitor
- XL-228 SRC inhibitor